MP07-11 REAL WORLD MEDICATION PERSISTENCE IN TREATMENT OF WOMEN WITH OVERACTIVE BLADDER ACCORDING TO LARGE SCALE PRESCRIPTION CLAIMS DATA

Abstract

You have accessJournal of UrologyCME1 May 2022MP07-11 REAL WORLD MEDICATION PERSISTENCE IN TREATMENT OF WOMEN WITH OVERACTIVE BLADDER ACCORDING TO LARGE SCALE PRESCRIPTION CLAIMS DATA Chen Shenhar, Karin Lifshitz, Igor Mintz, Yariv Shtabholtz, Ofer Yossepowitch, Jack Baniel, and Shachar Aharony Chen ShenharChen Shenhar More articles by this author , Karin LifshitzKarin Lifshitz More articles by this author , Igor MintzIgor Mintz More articles by this author , Yariv ShtabholtzYariv Shtabholtz More articles by this author , Ofer YossepowitchOfer Yossepowitch More articles by this author , Jack BanielJack Baniel More articles by this author , and Shachar AharonyShachar Aharony More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002529.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Medical treatments for overactive bladder (OAB) have proven efficacy in controlled trials. However, 1-year medication persistence is reported to be as low as 25% for anticholinergics and 40% for β3 agonists. Real world data on treatment continuation and sequence in case of medication replacement is limited. Our aim was to study actual treatment persistence trends in women initiated on OAB medications. METHODS: We used advanced data-mining techniques to explore the largest regional provider’s medication purchase database, dispensing for over 400,000 patients, for all women initiating OAB pharmacotherapy between 2010 and 2020, and cross-referenced them with patient age, BMI, and smoking status. Medication persistence was measured in days for which the patient was issued a medication, and prescription non-refilling for 90 days was defined as non-persistence. We employed a Sankey diagram to map trends in OAB medication claims and treatment sequence. We further compared medication persistence using Kaplan-Meier survival curves and pairwise log-rank analysis. We studied the effects of age and smoking status on medication continuation using logistic regression modelling. RESULTS: Between 2010 and 2020, 46,079 women made 791,681 unique acquisitions of OAB medications. Overall treatment persistence rates were 49% for 30 days, 34% for 90 days, and 9% for a year. The 1-year persistence rate was highest for Mirabegron (10%) and Oxybutynin (11%) compared with all other medications (4%) (p<0.005). Overall persistence rates were unchanged when stratifying by time of Mirabegron acceptance into insurance coverage (p>0.05). Patients persisting with treatment for over 90 days were 5 years older compared to their non-persisting counterparts (mean age 72.8±14.3 vs. 67.5±16.5 years, p<0.05). Non-smokers had an odds ratio of 1.1 [95% CI: 1.04-1.16] of persistence when compared to smokers. CONCLUSIONS: Real-world OAB pharmacotherapy persistence rates are lower than previously reported. The added option of Mirabegron did not seem to improve these rates. Source of Funding: none © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e119 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Chen Shenhar More articles by this author Karin Lifshitz More articles by this author Igor Mintz More articles by this author Yariv Shtabholtz More articles by this author Ofer Yossepowitch More articles by this author Jack Baniel More articles by this author Shachar Aharony More articles by this author Expand All Advertisement PDF DownloadLoading ...